Key facts
- This page summarizes Zafrira Avnur's Form 4 filing for Eloxx Pharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2022, 08:23.
Zafrira Avnur - 15 Jun 2022 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- ELOX on Nasdaq
- Reported as of
- 15 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2022, 08:23:51 UTC
- Prior SEC filing
- 20 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sumit Aggarwal, Attorney-in-Fact for Zafrira Avnur
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Zafrira Avnur filed Form 4 for Eloxx Pharmaceuticals, Inc. on 17 Jun 2022.
Change
- Previous filing in this sequence was filed on 20 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELOX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 15 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $0.2600
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal installments thereafter.